Table 6.

Sensitivities for individual and combined tumor marker assays in stage II – IV endometrial cancer.

Marker Combination	Controls vs. Endometrial Cancers – Stage II-IV Average Sensitivity at Set Specificity of:
	90%	95%	98%
CA125	46.7%	32.9%	22.4%
HE4	71.4%	64.9%	55.1%
CA72.4	17.6%	12.2%	7.0%
SMRP	16.6%	16.2%	12.5%
CA125 + HE4	73.0%	69.7%	52.7%
CA125 + CA72.4	38.8%	30.6%	24.5%
CA125 + SMRP	47.0%	39.4%	20.4%
HE4 + CA72.4	71.4%	65.3%	55.1%
HE4 + SMRP	73.4%	59.5%	49.0%
CA125 + HE4 + CA72.4	72.5%	69.4%	53.5%
CA125 + HE4 + SMRP	73.3%	63.3%	57.3%
CA125 + CA72.4 + SMRP	49.0%	30.8%	27.3%
HE4 + CA72.4 + SMRP	73.5%	61.0%	49.1%
CA125 + HE4 + CA72.4 + SMRP	73.4%	62.1%	57.3%